Skip to main content

Bharat Neeti

BHARAT NEETI

Be Ahead With Economy And Policy Updates

192x192 - PWA

BHARAT NEETI

Be Ahead With Economy And Policy Updates

NATCO Pharma Receives U.S. FDA Inspection Report for FDF Facility

(Image Courtesy: NATCO Pharma Limited)
(Image Courtesy: NATCO Pharma Limited)
WhatsApp
Copy link
URL has been copied successfully!
Hyderabad: NATCO Pharma Limited (BSE: 524816, NSE: NATCOPHARM) has received the Establishment Inspection Report (EIR) from the U.S. Food and Drug Administration (FDA) for its finished dosage formulations (FDF) manufacturing plant in Parawada, Visakhapatnam, Andhra Pradesh.

The U.S. FDA conducted the inspection from August 17 to August 21, 2026. At the conclusion of the inspection, the company received four observations in Form 483.

NATCO Pharma has now received the EIR classifying the inspection as Voluntary Action Indicated (VAI).

The company disclosed this information pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Leave a Reply

Your email address will not be published. Required fields are marked *

You are warmly welcomed to India’s first On-Demand News Platform. We are dedicated to fostering a democracy that encourage diverse opinions and are committed to publishing news for all segments of the society. If you believe certain issues or news stories are overlooked by mainstream media, please write to us. We will ensure your news is published on our platform. Your support would be greatly appreciated if you could provide any relevant facts, images, or videos related to your issue.

Contact Form Demo